The objective of this study was to evaluate the effects of sodium glucose co-transporter
2 inhibitors (SGLT2i) on functional capacity and diastolic function in patients with
diabetes with nonobstructive hypertrophic cardiomyopathy (nHCM) and preserved left
ventricular (LV) function. From January 2019 to October 2020, a prospective open-label
study was performed on patients with type 2 diabetes mellitus and nHCM with New York
Heart Association class II-III symptoms. Patients with a LV ejection fraction <50%
were excluded. Patients were recruited from January 2019 to November 2019 to the SGLT2i
arm and from November 2019 to October 2020 to the control arm. The primary composite
end point was defined as achieving an improvement of at least 1.5 in E/e′ and a reduction
of ≥1 New York Heart Association functional class after 6 months of therapy. At baseline,
there were no significant differences between the SGLT2i (n = 24) and control arms
(n = 24). More patients in the SGLT2i arm achieved the primary end point than the
patients in the control arm (70.8% vs 4.2%, p <0.001). After 6 months of therapy,
patients in the SGLT2i arm showed a significant improvement in all diastolic function
parameters (E/e′ 16.3 ± 1.9 vs 13.3 ± 1.6, p <0.001; E/A 2.8 ± 0.1 vs 2.4 ± 0.1, p
<0.001; left atrial volume 45.6 ± 5.2 vs 40.8 ± 4.9 ml/m2, p = 0.003). There was also an improvement in the 6-minute walk distance (295.1 ±
31.5 vs 343.0 ± 31.1 m, p <0.001) and N-terminal pro-B-type natriuretic peptide (481.4
± 52.6 vs 440.9 ± 43.9 pg/ml, p <0.001) in patients who received SGLT2i. There was
no significant change in the LV mass in the SGLT2i or control arm (−0.1 ± 0.3 vs 0.1
± 0.5 g/m2, p = 0.319) after 6 months of therapy. A patient in the SGLT2i arm discontinued therapy
because of a urinary tract infection. In conclusion, the use of SGLT2i improved diastolic
function and functional capacity in patients with diabetes with nHCM and a preserved
LV function.
Graphical Abstract
Graphical Abstract
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to American Journal of CardiologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Contemporary natural history and management of nonobstructive hypertrophic cardiomyopathy.J Am Coll Cardiol. 2016; 67: 1399-1409
- Nonobstructive hypertrophic cardiomyopathy out of the shadows: known from the beginning but largely ignored... until now.Am J Med. 2017; 130: 119-123
- Clinical outcomes in patients with nonobstructive, labile, and obstructive hypertrophic cardiomyopathy.J Am Heart Assoc. 2018; 7e006657
- Metabolic changes in hypertrophic cardiomyopathies: scientific update from the Working Group of Myocardial Function of the European Society of Cardiology.Cardiovasc Res. 2018; 114: 1273-1280
- Novel approach targeting the complex pathophysiology of hypertrophic cardiomyopathy: the impact of late sodium current inhibition on exercise capacity in subjects with symptomatic hypertrophic cardiomyopathy (LIBERTY-HCM) trial.Circ Heart Fail. 2016; 9e002764
- Efficacy of ranolazine in patients with symptomatic hypertrophic cardiomyopathy: the RESTYLE-HCM randomized, double-blind, placebo-controlled study.Circ Heart Fail. 2018; 11e004124
- Effect of trimetazidine dihydrochloride therapy on exercise capacity in patients with nonobstructive hypertrophic cardiomyopathy: a randomized clinical trial.JAMA Cardiol. 2019; 4: 230-235
- DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction.N Engl J Med. 2019; 381: 1995-2008
- Empagliflozin in heart failure with a preserved ejection fraction.N Engl J Med. 2021; 385: 1451-1461
- Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review.JACC Basic Transl Sci. 2020; 5: 632-644
- Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.Eur Heart J Cardiovasc Imaging. 2015; 16: 233-270
- Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.Eur Heart J Cardiovasc Imaging. 2016; 17: 1321-1360
- Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings.Am J Cardiol. 1986; 57: 450-458
- Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes.Cardiovasc Diabetol. 2018; 17: 73
- Effect of empagliflozin on left ventricular mass and diastolic function in individuals With diabetes: an important clue to the EMPA-REG OUTCOME trial?.Diabetes Care. 2016; 39: e212-e213
- Randomized, controlled trial to evaluate the effect of dapagliflozin on left ventricular diastolic function in patients with type 2 diabetes mellitus: the IDDIA trial.Circulation. 2021; 143: 510-512
- Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure.Cardiovasc Diabetol. 2018; 17: 132
- A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial.Eur Heart J. 2020; 41: 3421-3432
- Empagliflozin improves diastolic function in a nondiabetic rodent model of heart failure with preserved ejection fraction.JACC Basic Transl Sci. 2019; 4: 27-37
- EMPEROR-Preserved Trial Committees and Investigators. Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial.Eur J Heart Fail. 2020; 22: 2383-2392
- Stratified Treatment of Heart Failure with preserved Ejection Fraction: rationale and design of the STADIA-HFpEF trial.ESC Heart Fail. 2020; 7: 4478-4487
- Hypertrophic cardiomyopathy: a heart in need of an energy bar?.Front Physiol. 2014; 5: 309
- Empagliflozin increases cardiac energy production in diabetes: novel translational insights into the heart failure benefits of SGLT2 inhibitors.JACC Basic Transl Sci. 2018; 3: 575-587
Article info
Publication history
Published online: December 03, 2022
Received in revised form:
October 24,
2022
Received:
June 21,
2022
Footnotes
Drs. Sravani, Krishna, and Bijjam contributed equally to this work.
Funding: None.
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
